FLT3-IN-17 - ≥99% , CAS No.2758999-62-9

CAS: 2758999-62-9 Cat. No.: F1440103 Formule: C₂₃H₂₄N₆O₂S₂ Poids moléculaire: 480.61

GRADE & PURITY ≥99%

Storage

Store at 2-8°C,Desiccated

Shipped In

Wet ice

Vue d’ensemble

FLT3-IN-17 inhibits CYPs and FLT3 mutants activity ( IC 50 s: <0.5 nM for D835Y). FLT3-IN-17 is also a FAK inhibitor, with an IC 50 value of 12 nM. FLT3 ligand-2 can be used in the research of cancers.

Specifications

Spécifications et pureté

≥99%

Conditions de stockage de stockage

Store at 2-8°C,Desiccated

Expédié en

Wet ice

Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.

Type d'action

INHIBITOR

Pureté

≥99%

Noms et identifiants

Poids moléculaire

480.61

Application Protocols

No tested application protocols, recommended dilutions, or reference controls are provided in the Product Data for this item.

Guidance:

• Please refer to the CoA/Spec Sheet and SDS for any lot-specific handling notes.
• If you require example workflows (e.g., stock preparation, dilution series, or kinase assay setup), contact technical support; any shared methods will be clearly labeled as general guidance and not specifications for this product.

Biological Roles

Item-specific biological claims: Not specified for this item; no target specificity or potency data are provided in the Product Data.

General background on FLT3 biology (literature, not item-specific):

• FLT3 (Fms-like tyrosine kinase 3; CD135) is a class III receptor tyrosine kinase expressed predominantly in hematopoietic progenitor cells. Ligand binding (FLT3 ligand) promotes receptor dimerization and activation of downstream pathways including MAPK/ERK, PI3K/AKT, and STAT5, supporting proliferation and survival of hematopoietic lineages.
• Dysregulation: Internal tandem duplications (ITD) and tyrosine kinase domain (TKD) point mutations can drive constitutive FLT3 signaling, a key topic in leukemia research.
• Research tools: Small-molecule modulators are commonly used to dissect signaling, validate targets, and benchmark assay systems. Typical readouts include phosphorylation status of FLT3 and downstream effectors, cell viability, apoptosis markers, and transcriptional responses.

Experimental considerations (general):

• Use appropriate control cell lines (e.g., engineered FLT3-expressing systems or lines harboring defined mutations) and include orthogonal assays (biochemical vs cellular) to confirm on-target effects.
• Control for DMSO concentration and time-in-culture to reduce variability in signaling.
• Incorporate counter-screens to identify potential off-target kinase interactions.

Important: None of the above constitutes a claim about FLT3-IN-17’s activity or selectivity; consult CoA or primary literature for compound-specific information if available.

Buffer Applications

Not typically applicable as a buffering agent. FLT3-IN-17 is a small-molecule research compound and is not intended to establish or maintain pH.

General assay buffer guidance (not item-specific):

• Biochemical kinase assays: Commonly use HEPES (25–50 mM, pH 7.4), 0.01–0.05% Tween-20, 5–10 mM MgCl2, and DTT or TCEP as reductant if compatible with detection. Maintain constant DMSO across all wells.
• Cellular assays: Culture medium per cell-line requirements; for acute compound treatment, serum reduction or starvation may be used before ligand stimulation to reduce basal signaling.
• Solubility control: Add compound stocks to vigorously mixed buffers/media to avoid local supersaturation; pre-warm to room temperature.

Item-specific buffer compatibility, pH stability, or precipitation thresholds are not provided; refer to the CoA/Spec Sheet or perform a small-scale solubility screen when establishing new assays.

Green Alternatives

Although this product is a small-molecule tool compound rather than a solvent or reagent, greener choices can be made in its handling and assay workflows (general guidance, not item-specific):

Greener solvent considerations for stock prep and dilution:

• Prefer DMSO over DMF or NMP when possible due to lower regulatory concern and broad assay compatibility.
• Use ethanol or aqueous cosolvent systems where compound solubility and assay tolerance permit.
• Minimize solvent volumes and choose microplate materials that reduce adsorption, limiting the need for high solvent content.

Comparison (general):

• DMSO vs DMF/NMP
  • Occupational profile: DMSO generally preferred over DMF/NMP (reproductive toxicity concerns with the latter; consult SDS).
  • Assay compatibility: DMSO widely validated at ≤1% v/v; DMF/NMP often less tolerated biologically.
• Aqueous buffer + low % DMSO vs pure organic vehicles
  • Waste reduction: Mixed aqueous systems reduce hazardous organic waste.
  • Performance: Requires ensuring compound remains in solution; add small surfactant amounts if compatible with assay.

Operational greening:

• Adopt miniaturized assays (384/1536-well) to reduce compound and solvent use.
• Implement plate sealing to limit evaporation and rework.
• Consolidate shipments and store desiccated at 2–8°C as specified to maintain stability and avoid repeated synthesis.

Note: No greener “alternative compound” to FLT3-IN-17 is suggested here, as target and structure are not provided. Optimize the workflow’s environmental footprint instead.

Pharmaceutical Uses

No pharmacopeial status, excipient role, or formulation claims are provided for this item. It is supplied strictly for research use only.

General R&D context (not item-specific):

• Discovery research: Small-molecule FLT3-pathway modulators are often employed as reference or exploratory tool compounds to interrogate signaling pathways, benchmark screening platforms, or support target validation.
• Preformulation screening: Researchers may evaluate solubility, permeability (e.g., PAMPA, Caco-2), metabolic stability (microsomes/hepatocytes), and protein binding as part of profiling. Such activities are exploratory and not indicative of suitability for clinical use.
• Manufacturing/scale-up: Not applicable here; this listing does not include GMP grade, IMP status, or clinical development information.

Compliance note:

• This product is labeled For research use only and is not intended for human or veterinary use, diagnostics, or as a drug substance/excipient in commercial formulations.

Physical Properties

Item-specific facts (from Product Data):

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
• Physical constants (BP, MP, density, refractive index): Not specified for this item; refer to CoA/Spec Sheet.
• Solubility and logP: Not specified for this item; refer to CoA/Spec Sheet.

General/literature guidance for small-molecule kinase tool compounds (not item-specific):

• Physical state: Many FLT3-focused tool compounds are crystalline or amorphous solids at ambient temperature.
• Solubility handling: DMSO is commonly used to prepare concentrated stocks (e.g., 10–50 mM), followed by dilution into assay buffers containing a small percentage of DMSO (typically ≤1% v/v) to minimize solvent effects.
• Aqueous behavior: Solubility in purely aqueous media can be limited; use of co-solvents (DMSO, ethanol) or formulation aids (0.01–0.1% nonionic surfactant) is sometimes employed in screening contexts.
• pKa/logP: Kinase inhibitors often contain heteroaromatic nitrogens and amide/urea motifs with pKa values that influence ionization near physiological pH, and logP/logD in the moderate range to enable target engagement (broad literature trends; not specific to this item).

Important note: Do not treat the above as specifications for FLT3-IN-17. For lot-specific, authoritative physical data, consult the CoA/Spec Sheet and SDS.

Quality and Grades

Item-specific facts (from Product Data):

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.

Research-use context:

• This product is designated “For research use only.” It is not intended for diagnostic or therapeutic use.

Understanding grades (general guidance, not item-specific):

• Research grade: Suitable for discovery biology, biochemical assays, and method development; acceptance criteria commonly include HPLC purity and identity by MS/NMR.
• HPLC/LC-MS suitability: For kinase screening, low UV background and a clean chromatographic profile are advantageous, especially for readouts that rely on UV absorbance or LC–MS endpoints.
• Stabilizers: Some small molecules are shipped with desiccants or under inert atmosphere to preserve integrity. No stabilizer is specified for this item.

What to check on the CoA/Spec Sheet (practical notes):

• Identity: LC–MS m/z, 1H NMR signature, and retention time.
• Purity: HPLC area % methodology (wavelengths, gradient, and column).
• Residual solvents and water content: Karl Fischer and GC residual solvent profile, if available.
• Lot-specific storage and retest/expiry date: Ensures fitness for use in screening campaigns.

Conclusion:

• For definitive grade, purity, impurity profile, and test methods for FLT3-IN-17, please refer to the item’s CoA/Spec Sheet and SDS.

Reaction and Applications

This item is a small-molecule research compound; it is not primarily intended as a synthetic reagent.

Applications in discovery biology (general guidance, not item-specific):

• Biochemical kinase assays: Used as a test article in FLT3 or related tyrosine kinase enzyme assays to generate dose–response curves (IC50/Ki determination). Employ appropriate ATP concentrations (e.g., near Km), Mg2+ cofactors, and peptide/protein substrates.
• Cellular assays: Evaluate effects on signaling readouts (e.g., phospho-FLT3, phospho-STAT5) by Western blot or ELISA using serum-starved cells followed by ligand stimulation. Ensure consistent DMSO across treated and control groups.
• Selectivity profiling: Broad kinase panels or NanoBRET/thermal shift profiling to understand engagement and off-targets (general technique; target specificity for this item is not provided).
• Physicochemical assessment: Solubility, stability in assay buffers, and potential aggregation (test with detergent controls or dynamic light scattering) to validate mechanism.

Practical tips (general):

• Prepare fresh DMSO stocks for critical measurements; filter stocks (0.2 µm PTFE) to reduce particulates.
• Include counter-screens (e.g., luciferase interference, redox cycling assays) to avoid false positives.
• Record exact DMSO % and temperature; compound potency can be sensitive to these parameters.

Item-specific activity claims for FLT3-IN-17 are not provided in this listing; consult primary data or CoA if available.

Reaction Conditions

Not applicable as a chemical reactant. No synthetic reaction conditions are provided or implied for this item.

General guidance for biological assay conditions (not item-specific):

• Biochemical FLT3 assays: Typical buffers include 25–50 mM HEPES (pH 7.4), 5–10 mM MgCl2, 0.1 mg/mL BSA, 1 mM DTT; ATP at or near Km; substrate peptide/protein per kit/vendor recommendation. Incubations often run 10–60 min at 25–30°C. Detection modalities include radiometric, ADP-Glo, TR-FRET, or LC–MS.
• Cellular assays: Exposure windows commonly range from 0.5–4 h for acute signaling readouts and 24–72 h for viability assays, with solvent (DMSO) ≤0.1–0.5% v/v unless otherwise validated.
• Serial dilutions: Prepare geometric dilution series in DMSO, then spike into assay plates to achieve uniform final solvent content across wells.

Important: The above are literature-style, general practices and not specifications for FLT3-IN-17. For this specific product, no activity, potency, or preferred assay conditions are provided. Validate conditions empirically and consult the CoA/Spec Sheet for any available guidance.

Safety and Handling

Item-specific hazard information (from Product Data):

• Signal Word: Not specified for this item; refer to SDS.
• H-Statements: Not specified for this item; refer to SDS.
• GHS Classification: Not specified for this item; refer to SDS.
• Pictograms: Not specified for this item; refer to SDS.

Storage and shipping (item-specific):

• Storage Conditions: Store at 2–8°C, desiccated.
• Shipped In: Wet ice.

General laboratory safety guidance (not item-specific):

• PPE: Wear lab coat, safety glasses, and appropriate chemical-resistant gloves. Work in a chemical fume hood when handling powders or preparing solutions.
• Hygiene: Avoid inhalation of dust/aerosols. Prevent skin/eye contact. Wash hands thoroughly after handling.
• Incompatibilities: Avoid strong oxidizers and strong acids/bases until specific compatibility data are known (general precaution for organic small molecules).
• Spill/Exposure: For small spills, absorb with inert material and dispose according to institutional procedures. On skin/eye contact, rinse with water for at least 15 minutes and seek medical attention per SDS guidance.
• Thermal/photostability: In absence of item-specific data, protect from excessive heat and light; keep container tightly closed with desiccant to minimize hydrolysis or moisture uptake.

Authoritative reference: Always consult the Safety Data Sheet (SDS) for definitive hazard classification, first-aid measures, firefighting measures, and disposal instructions for the specific lot.

Solvent Selection

Item-specific solubility: Not specified for this item; refer to CoA/Spec Sheet.

General solvent guidance for small-molecule screening stocks (not item-specific):

• Primary solvent: DMSO is the standard for preparing concentrated small-molecule stocks (e.g., 10–50 mM), due to broad solubilization capability and compatibility with enzyme and cell assays at ≤0.1–1% v/v.
• Alternative co-solvents: Ethanol or DMF can be used for pre-dissolution; final assay solutions should minimize organic content and include appropriate controls.
• Aqueous buffers: HEPES or Tris buffers (pH 7.2–7.5) with 0.01–0.05% nonionic surfactant (e.g., Tween-20 or Pluronic F-127) may help maintain clarity upon dilution from DMSO (general practice).
• Avoid precipitation: Add compound stock last to well-mixed buffer; maintain consistent DMSO across wells/controls; pre-warm to room temperature to reduce microprecipitates.

Polarity/miscibility profile (general):

• DMSO: Polar aprotic, fully miscible with water; high boiling point simplifies deck handling but necessitates careful evaporation control.
• Ethanol: Protic, fully miscible with water; faster evaporation can alter concentrations on open decks.

Comparison (general, not item-specific):

• DMSO vs ethanol for stock prep:
  • Solubilization breadth: DMSO > ethanol for many heteroaromatics.
  • Assay tolerance: DMSO commonly tolerated up to 0.1–1% v/v; ethanol tolerance may be lower for some cells/enzymes.
  • Stability: Many compounds exhibit better stability in dry DMSO when stored desiccated and cold.

Storage and Reconstitution

Item-specific storage and shipping (from Product Data):

• Storage Conditions: Store at 2–8°C, desiccated.
• Shipped In: Wet ice.

Item-specific reconstitution details: Not specified for this item; refer to CoA/Spec Sheet.

General reconstitution guidance for small-molecule screening stocks (not item-specific):

• Solvent: Dry DMSO is commonly used to prepare concentrated stocks (e.g., 10–50 mM). If aqueous use is required, dilute the DMSO stock into buffer with vigorous mixing to the desired final concentration, maintaining consistent DMSO % across samples.
• Filtration: If particulates are observed, pass solution through a 0.2 µm PTFE filter.
• Aliquoting: Prepare single-use aliquots to avoid repeated freeze–thaw cycles and moisture ingress.
• Storage of solutions: Store DMSO stocks refrigerated (2–8°C) or frozen (−20°C) in tightly sealed, desiccated containers. Protect from light if the compound is chromophoric; confirm stability empirically.

Stability disclaimer:

• Without item-specific data, do not assume stability beyond your verified window. Consult the CoA/Spec Sheet for any lot-specific retest date or stability notes and follow SDS guidance for safe handling.

Structure and Identity

Overview: This listing is for a small-molecule research compound labeled FLT3-IN-17, typically used in kinase-targeted discovery workflows.

Item-specific facts (from Product Data):

• SKU: F1440103
• Product Name: FLT3-IN-17
• CAS: 2758999-62-9
• Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.

Structural features (general context):

• No structure is provided for this item. Based on the naming convention, compounds in the “FLT3-IN-*” series are typically small-molecule heteroaromatics or heteroarylamides designed to interact with the ATP-binding pocket of receptor tyrosine kinases (general chemistry knowledge). Specific ring systems, substitution patterns, stereochemistry, and functional groups for FLT3-IN-17 are not disclosed here.

2D structural description (not item-specific):

• FLT3 inhibitors frequently feature hydrogen-bond acceptors/donors aligned to hinge-binding motifs and hydrophobic appendages occupying selectivity pockets (literature, general medicinal chemistry). The exact 2D arrangement for FLT3-IN-17 is not provided in the current listing.

Identity confirmation:

• For definitive identity (structure, purity, and analytical data: NMR, LC–MS, HPLC), please consult the Certificate of Analysis (CoA) and/or Specification Sheet associated with the specific lot.

Synthetic Utility

This product is supplied as a finished small-molecule research compound and is not positioned as a synthetic reagent or building block.

General medicinal chemistry perspective (not item-specific):

• Kinase-focused scaffolds often incorporate hinge-binding heterocycles (e.g., purines, quinazolines, pyrimidines) and solubilizing side chains. While such motifs are synthetically modular, this catalog entry does not provide a structure for FLT3-IN-17, and no guidance can be given on derivatization or late-stage functionalization for this item.
• If structure is available in your program, typical transformations to explore SAR might include amide couplings, SNAr on activated heteroaromatics, Buchwald–Hartwig or Suzuki couplings to elaborate aryl/heteroaryl vectors, and urea/carbamate formations (general literature strategies).

Item-specific synthetic handles, protecting group strategies, and functional group compatibility: Not specified for this item; refer to CoA/Spec Sheet or internal project documentation if derivatization is intended.

Conclusion: Treat FLT3-IN-17 as a research tool compound rather than a reagent; for synthetic campaigns, obtain structural disclosure and route development separately.

Target Specificity

Item-specific target data: Not specified for this item; refer to CoA/Spec Sheet.

Notes:

• Despite the product name suggesting relevance to FLT3 research, no binding, enzymatic, cellular potency, or selectivity data are provided in this listing.
• Users should consult internal data, peer-reviewed literature, or contact technical support for any available characterization.

Policy reminder: Only target information contained in the Product Data or CoA should be treated as authoritative for this item.

Foire aux questions

What is the purity of this product?

This product is supplied at ≥99% purity (chemical assay). Lot-specific values are stated on the Certificate of Analysis.

How should this product be stored?

Store at 2–8 °C, desiccated. Keep the container tightly closed with desiccant — the material is moisture-sensitive.

How is this product shipped?

This product ships chilled on wet ice. Unpack on arrival and transfer it to the storage condition stated above.

What are the CAS number, molecular formula and molecular weight?

The CAS Number is 2758999-62-9, the molecular formula is C23H24N6O2S2, and the molecular weight is 480.61 g/mol.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.